Market needs a better mousetrap than a PCR based t
Post# of 9122
Nnlx has an open door. We need to show that our technology works and we have a product application for COvid 19 and other pathogens. That’s the big IF. I do not think PCR dominance over channels of distribution for testing is a hurdle for much longer.